+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Diabetic Neuropathy Drugs Market 2019-2023 - Product Image

Global Diabetic Neuropathy Drugs Market 2019-2023

  • ID: 4764971
  • Report
  • March 2019
  • Region: Global
  • 135 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • MORE
The rising awareness about diabetic neuropathy is one of the prominent factors likely to contribute to the diabetic neuropathy drugs market growth in the forthcoming years. Several awareness programs are being launched among the consumers with an aim to educate and train diabetes educators in the emerging and advanced economies. Different campaigns are encouraging people to take an online test for knowing about the risk factors associated with prediabetes, in turn, driving the diabetic neuropathy drugs market growth during the forecast period. The analysts have predicted that the diabetic neuropathy drugs market will register a CAGR of about 6% by 2023.

Market Overview

New drug approvals and strong drug pipeline

One of the growth drivers of the global diabetic neuropathy drugs market is new drug approvals and strong drug pipeline. With the rising prevalence of diabetic neuropathy, several market players are focusing on the development of disease-modifying drugs to treat the disease.

Side-effects of major drugs

One of the challenges in the growth of the global diabetic neuropathy drugs market is the side-effects of major drugs. Side-effects associated with approved drugs such as pregabalin (LYRICA) and gabapentin (NEURONTIN) can lead to low patient compliance, thereby hindering the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the diabetic neuropathy drugs market during 2019-2023, view this report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. Vendors in the market are focusing on the development of novel biologics to treat diabetic neuropathy. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: CUSTOMER LANDSCAPE

PART 07: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 08: MARKET SEGMENTATION BY MECHANISM OF ACTION
  • Market segmentation by mechanism of action
  • Comparison by mechanism of action
  • Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023
  • SNRIs and TCAs - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by mechanism of action
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Customer landscape
Exhibit 19: Market share by geography 2018-2023 (%)
Exhibit 20: Geographic comparison
Exhibit 21: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: North America - Year-over-year growth 2019-2023 (%)
Exhibit 23: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 25: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 27: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 29: Key leading countries
Exhibit 30: Market opportunity
Exhibit 31: Mechanism of action - Market share 2018-2023 (%)
Exhibit 32: Comparison by mechanism of action
Exhibit 33: Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Calcium channel alpha-2-delta ligand - Year-over-year growth 2019-2023 (%)
Exhibit 35: SNRIs and TCAs - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: SNRIs and TCAs - Year-over-year growth 2019-2023 (%)
Exhibit 37: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Others - Year-over-year growth 2019-2023 (%)
Exhibit 39: Market opportunity by mechanism of action
Exhibit 40: Decision framework
Exhibit 41: Pipeline drugs for diabetic neuropathy
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Biologics under development
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor_analysis1
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: DAIICHI SANKYO COMPANY, LIMITED - Vendor overview
Exhibit 51: DAIICHI SANKYO COMPANY, LIMITED - Business segments
Exhibit 52: DAIICHI SANKYO COMPANY, LIMITED - Organizational developments
Exhibit 53: DAIICHI SANKYO COMPANY, LIMITED - Geographic focus
Exhibit 54: DAIICHI SANKYO COMPANY, LIMITED - Segment focus
Exhibit 55: DAIICHI SANKYO COMPANY, LIMITED - Key offerings
Exhibit 56: Eli Lilly and Company - Vendor overview
Exhibit 57: Eli Lilly and Company - Business segments
Exhibit 58: Eli Lilly and Company - Organizational developments
Exhibit 59: Eli Lilly and Company - Geographic focus
Exhibit 60: Eli Lilly and Company - Segment focus
Exhibit 61: Eli Lilly and Company - Key offerings
Exhibit 62: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 63: Johnson & Johnson Services, Inc. - Business segments
Exhibit 64: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 65: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 66: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 67: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 68: Novartis AG - Vendor overview
Exhibit 69: Novartis AG - Business segments
Exhibit 70: Novartis AG - Organizational developments
Exhibit 71: Novartis AG - Geographic focus
Exhibit 72: Novartis AG - Segment focus
Exhibit 73: Novartis AG - Key offerings
Exhibit 74: Pfizer Inc. - Vendor overview
Exhibit 75: Pfizer Inc. - Business segments
Exhibit 76: Pfizer Inc. - Organizational developments
Exhibit 77: Pfizer Inc. - Geographic focus
Exhibit 78: Pfizer Inc. - Segment focus
Exhibit 79: Pfizer Inc. - Key offerings
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Diabetic Neuropathy Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global diabetic neuropathy drugs market: DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel biologics to treat diabetic neuropathy.”

According to the report, one of the major drivers for this market is the new drug approvals and strong drug pipeline.

Further, the report states that one of the major factors hindering the growth of this market is the side-effects of major drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll